Pureos Bioventures — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
AnaCardio is a Swedish clinical-stage biopharmaceutical company developing novel drugs to treat heart failure, with its lead program AC01 in phase 1b/2a clinical development.
BiotechHealthtechMedical DevicesStockholm, SE
Lars H. Lund(Founder)
Co-investors3B Future Health FundIndustrifondenNovo HoldingsSound Bioventures
PulseSight Therapeutics develops non-viral, plasmid-based gene therapies delivered via a proprietary electro-transfection system into the ciliary muscle to treat severe retinal diseases causing blindness.
BiotechHealthtechMedical Devices
Co-investors+ND Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.


